dc.contributor.advisor | Yasmin, Hasina | |
dc.contributor.author | Tabassum, Nadira | |
dc.date.accessioned | 2024-05-19T08:17:32Z | |
dc.date.available | 2024-05-19T08:17:32Z | |
dc.date.copyright | ©2023 | |
dc.date.issued | 2023-10 | |
dc.identifier.other | ID 19346012 | |
dc.identifier.uri | http://hdl.handle.net/10361/22868 | |
dc.description | This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. | en_US |
dc.description | Cataloged from PDF version of thesis. | |
dc.description | Includes bibliographical references (pages 37-41). | |
dc.description.abstract | Alzheimer’s disease is a neurodegenerative disease. Using FDA Adverse Event Reporting
System database, a pharmacovigilance study for gender specific rhabdomyolysis risk in
memantine users was conducted between January 2016-June 2023. “R” statistical tool was used
to calculate the reporting odds ratio (95%CI), which serves as a signal index. Memantine
showed a signal, when the whole dataset is used as a comparator, but not when AChEIs are
used. ROR,95% CI value for male memantine consumers 5.68 (2.12 - 15.19), for female 7.98
(2.55-24.70) while using whole dataset as comparator. Again, male patients value is 1.40 (0.46
- 4.26), whereas 2.53 (0.65 - 9.83) for females, using AChEIs as comparator. Females have a
higher risk of developing rhabdomyolysis than males as the ROR value was higher for them in
both comparisons. Thus, data shows memantine has a safer, more acceptable profile than
AChEIs & can be considered in comparison to other options. | en_US |
dc.description.statementofresponsibility | Nadira Tabassum | |
dc.format.extent | 61 pages | |
dc.language.iso | en | en_US |
dc.publisher | Brac University | en_US |
dc.rights | Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. | |
dc.subject | Pharmacovigilance | en_US |
dc.subject | Alzheimer disease | en_US |
dc.subject | Dementia | en_US |
dc.subject | Rhabdomyolysis | en_US |
dc.subject.lcsh | Alzheimer's disease | |
dc.subject.lcsh | Dementia | |
dc.title | Gender-specific Rhabdomyolysis risk in Alzheimer’s disease patients receiving memantine: a pharmacovigilance study | en_US |
dc.type | Thesis | en_US |
dc.contributor.department | School of Pharmacy, Brac University | |
dc.description.degree | B. Pharmacy | |